Simplify Logo

Full-Time

Head of Quality

Confirmed live in the last 24 hours

Roivant Sciences

Roivant Sciences

201-500 employees

Develops biopharmaceuticals and RNA therapeutics

Data & Analytics
Consulting
Hardware
Biotechnology
Consumer Goods

Senior, Expert

Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Communications
Management
Requirements
  • Bachelor's Degree is required in Biological Science, Chemistry or related technical discipline.
  • 15+ years’ experience in Biotech/Pharmaceutical industry, with ideally a minimum of 10 years in a supervisory capacity.
  • Expert working knowledge and interpretation of FDA/EU and ICH – GCP regulations and guidelines.
  • Broad and direct experience with regulatory authority inspections.
  • Strong experience working with outsourced support with track record of collaboratively engaging with external GxP 3rd parties to effectively execute Quality oversight.
  • Experienced in all phases of drug development is a plus.
  • Flexible in the face of shifting needs and/or priorities.
  • Able to interface well with all levels of personnel, including peers and other department heads such as: Clinical, Safety, Data Management, Biostatistics, Regulatory, CMC, and Project Management.
  • Experience with computerized systems and their associated compliance requirements.
  • Capacity to produce high quality results across multiple projects and demands, through effective prioritization, while working under short deadlines associated with a fast-paced dynamic scientific environment.
  • Excellent communications skills, both written and verbal.
  • Excellent teamwork, interpersonal skills and negotiation skills, both internally and externally.
  • Strategic thinker, open-minded and flexible to adopting new ideas.
Responsibilities
  • Responsible for the development, implementation, and strict adherence to a GxP quality program.
  • Develop phase appropriate processes and procedures for Roivant as well as select Vants, as needed.
  • Primary employee responsible for Quality decisions and execution on GMP, GCP, systems, qualification etc.
  • Oversee the drug substance, drug product, packaging/labeling/serialization, third-party logistics vendors for production activities of early and late-phase therapeutic areas.
  • Review and approve specifications affecting product quality and oversee the development of batch records, validation protocols.
  • Reviews and resolves quality issues with stakeholders and others including vendors, internal customers and production personnel.
  • Schedules and performs, as applicable, quality audits and reports findings to the company; ensures corrective action plans are developed there is a timely resolution of findings.
  • Prepares Quality Metrics for senior leadership supporting the quality function.
  • Ensure the appropriate Quality Management Systems in place to ensure GxP compliance.
  • Develop mutually agreeable Quality Agreements with Tier 1 vendors and vants. Support inspection readiness activities and associated Health Authority Inspections.
  • Develop/implement department specific standards and SOPs in support of the Quality System to satisfy best practices and regulatory requirements.
  • Work with management of GxP-regulated internal groups to identify process improvements for building compliance into the design and conduct of clinical activities.
  • Collaborate to ensure management of GxP regulated internal groups are actively engaged in improving compliance and addressing compliance risks.
  • Evaluate GxP compliance status in relationship to industry and Regulatory Agency expectations and assesses the effectiveness of corrective actions in response to internal and third-party audits.

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates by maximizing the potential of these candidates through a combination of in-house development and strategic partnerships, which helps build a strong pipeline of drugs. One of its key subsidiaries, Genevant, specializes in RNA therapeutics, utilizing proprietary delivery platforms for mRNA, RNAi, and gene editing to create effective treatments for specific diseases. Roivant generates revenue through licensing agreements, partnerships, and the sale of approved drugs, with the goal of bringing innovative treatments to market efficiently.

Company Stage

IPO

Total Funding

$2.3B

Headquarters

Basel, Switzerland

Founded

2014

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-25%
Simplify Jobs

Simplify's Take

What believers are saying

  • Roivant's recent $7.1B deal with Roche to acquire Telavant highlights its strong potential for lucrative partnerships and significant financial growth.
  • The company's diverse pipeline, including promising RNA therapeutics and gene editing technologies, offers substantial opportunities for breakthrough treatments.
  • Strategic investments, such as the $2.02 million from Exchange Traded Concepts LLC, indicate strong investor confidence and financial stability.

What critics are saying

  • The failure of the lupus drug brepocitinib in Phase 2 trials underscores the inherent risks in drug development and potential setbacks.
  • Rumors of acquiring Immunovant, Inc. could lead to financial strain and integration challenges if not managed properly.

What makes Roivant Sciences unique

  • Roivant Sciences leverages a unique business model that combines in-house product development with strategic partnerships, setting it apart from traditional biopharmaceutical companies.
  • The company's focus on RNA therapeutics and genetic disorders, particularly through its subsidiary Genevant, positions it at the forefront of cutting-edge medical treatments.
  • Roivant's ability to rapidly advance its drug pipeline and form strategic alliances allows it to bring innovative treatments to market more quickly and efficiently than many competitors.